The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer

Area of Science:

• Oncology
• Pharmacogenomics
• Biomarker Discovery

Background:

• Gefitinib was the first approved epidermal growth factor receptor (EGFR)-targeted therapy for nonsmall cell lung cancer (NSCLC).
• Its clinical development was complex, necessitating advances in understanding target biology.
• Biomarker identification became crucial to define patient populations likely to benefit.

Purpose of the Study:

• To evaluate the efficacy of gefitinib in a specific NSCLC patient subgroup.
• To confirm EGFR mutation as a predictive biomarker for gefitinib response.
• To inform the development of future personalized medicines.

Main Methods:

• Conducted the IRESSA Pan-Asia Study (IPASS) in East Asian never-smokers or former light-smokers with adenocarcinoma of the lung.
• Compared gefitinib versus carboplatin/paclitaxel as first-line therapy.
• Analyzed progression-free survival based on EGFR mutation status.

Main Results:

• EGFR mutation was the strongest predictor of improved progression-free survival (HR 0.48 for mutation-positive vs. HR 2.85 for mutation-negative).
• Gefitinib demonstrated significant benefit in EGFR mutation-positive patients.
• The study identified specific patient characteristics linked to higher EGFR mutation incidence and gefitinib response.

Conclusions:

• EGFR mutation status is a critical determinant of gefitinib efficacy in advanced NSCLC.
• Personalized medicine approaches, guided by biomarkers, are essential for optimizing cancer therapy.
• The findings provide valuable insights for developing future targeted cancer treatments.